Aprea Therapeutics Confirms Directors and Accounting Firm

Aprea Therapeutics ( (APRE) ) has provided an update.

At the 2025 annual meeting held on June 5, Aprea Therapeutics‘ stockholders voted on several key proposals. The election of three Class III directors, Jean-Pierre Bizzari, M.D., Oren Gilad, Ph.D., and John B. Henneman III, was confirmed to serve until the 2028 meeting. Additionally, EisnerAmper LLP was ratified as the independent public accounting firm for 2025. The stockholders also approved, through non-binding advisory votes, the compensation of named executive officers and the frequency of future votes on this compensation. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its leadership stability and financial oversight.

The most recent analyst rating on (APRE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.

Spark’s Take on APRE Stock

According to Spark, TipRanks’ AI Analyst, APRE is a Underperform.

Aprea Therapeutics receives a low overall score due to significant financial challenges, including consistent losses and lack of revenue generation. The company’s strong balance sheet is a positive but is offset by negative cash flows and a reliance on external financing. Technical indicators suggest a bearish trend, and the valuation is unattractive due to a negative P/E ratio and no dividend yield.

To see Spark’s full report on APRE stock, click here.

More about Aprea Therapeutics

Aprea Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of novel cancer therapeutics. The company is primarily engaged in advancing its proprietary small molecule drugs targeting the p53 tumor suppressor protein, with a market focus on oncology treatments.

Average Trading Volume: 27,861

Technical Sentiment Signal: Sell

Current Market Cap: $9.68M

See more data about APRE stock on TipRanks’ Stock Analysis page.